Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by ...
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...
Proton arc therapy offers a superior dose distribution compared with existing state-of-the-art proton delivery techniques ...
Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated ...
The Brighterside of News on MSN5d
New proton beam therapy precisely targets and destroys cancer cellsGlioblastoma, the most common and lethal form of primary brain cancer, presents daunting challenges. Each year, around 14,500 people in the United States face this aggressive disease. Its invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback